Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.

Münz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmüller G, Rüttinger D, Kufer P, Baeuerle PA, Raum T.

Cancer Cell Int. 2010 Nov 2;10:44. doi: 10.1186/1475-2867-10-44.


Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.

Lutterbuese P, Brischwein K, Hofmeister R, Crommer S, Lorenczewski G, Petersen L, Lippold S, da Silva A, Locher M, Baeuerle PA, Schlereth B.

Cancer Immunol Immunother. 2007 Apr;56(4):459-68. Epub 2006 Aug 26.


Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2010 Dec;20(9):1440-7.


In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.

Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmüller G, Baeuerle PA, Dreier T.

Int J Cancer. 2002 Jul 1;100(1):101-10.


Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Mol Cancer Ther. 2010 Jan;9(1):57-66. doi: 10.1158/1535-7163.MCT-09-0675. Epub 2010 Jan 6.


High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2010 Dec;203(6):582.e1-7. doi: 10.1016/j.ajog.2010.07.041. Epub 2010 Sep 25.


An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.

Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, Schmidt M, Rüttinger D, Schuler M, Reinhardt C, Awada A.

Ann Oncol. 2010 Feb;21(2):275-82. doi: 10.1093/annonc/mdp314. Epub 2009 Jul 24.


Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.

Kurtz JE, Dufour P.

Expert Opin Biol Ther. 2010 Jun;10(6):951-8. doi: 10.1517/14712598.2010.482098. Review.


Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.

Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ.

Br J Cancer. 2005 Jan 31;92(2):342-9.


Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.

Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmüller G, Willgeroth F, Sommer HL.

Clin Cancer Res. 1999 Dec;5(12):3999-4004.


A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients.

Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, Locher M, Prang N, Baeuerle PA, Leo E.

Eur J Cancer. 2006 Oct;42(15):2530-8. Epub 2006 Aug 23.


Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.

Schmidt M, Rüttinger D, Sebastian M, Hanusch CA, Marschner N, Baeuerle PA, Wolf A, Göppel G, Oruzio D, Schlimok G, Steger GG, Wolf C, Eiermann W, Lang A, Schuler M.

Ann Oncol. 2012 Sep;23(9):2306-13. doi: 10.1093/annonc/mdr625. Epub 2012 Feb 21.


High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS.

Mol Immunol. 2006 Mar;43(8):1183-93. Epub 2005 Aug 15.


EpCAM: A new therapeutic target for an old cancer antigen.

Armstrong A, Eck SL.

Cancer Biol Ther. 2003 Jul-Aug;2(4):320-6. Review.


Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities.

Robinson RR, Chartier J Jr, Chang CP, Horwitz AH, Better M.

Hum Antibodies Hybridomas. 1991 Apr;2(2):84-93.


Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines.

Sterzynska K, Kempisty B, Zawierucha P, Zabel M.

Folia Histochem Cytobiol. 2012;50(4):534-41. doi: 10.5603/17845.


Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.

Liao SK, Horton L, Flahart RE, O'Rear L, Crumpacker D, Imbaratto JW, Yannelli JR, Robinson RR, Oldham RK.

Hum Antibodies Hybridomas. 1990;1(2):66-76.


Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody.

Kirman I, Whelan RL.

Curr Opin Mol Ther. 2007 Apr;9(2):190-6.


Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model.

Kosterink JG, McLaughlin PM, Lub-de Hooge MN, Hendrikse HH, van Zanten J, van Garderen E, Harmsen MC, de Leij LF.

J Immunol. 2007 Jul 15;179(2):1362-8.

Supplemental Content

Support Center